Literature DB >> 35290501

Predisposing factors for a second fragile hip fracture in a population of 1130 patients with hip fractures, treated at Oulu University Hospital in 2013-2016: a retrospective study.

Nelli Helynen1, Lotta Rantanen2, Petri Lehenkari2,3,4, Maarit Valkealahti2,4.   

Abstract

OBJECTIVE: The life-time risk of a second fragile hip fracture is 8.4%, but the risk factors that predispose to a second hip fracture remain unresolved. This study aimed to define risk factors that predisposed patients to a second hip fracture.
METHODS: For this retrospective study, we retrieved clinical data on 1130 patients with fragile hip fractures (67.2% female, mean age: 79.3 years) that underwent surgery at the Oulu University Hospital in 2013-2016. These data included the fracture risk assessment score (measured with the FRAX tool), the bone-mass T-score, laboratory values, ambulatory capacity, and the time of death.
RESULTS: In this population, 12.4% of patients sustained a second hip fracture. The predisposing factors for a second hip fracture were: female (p = 0.016), a high FRAX score (p = 0.020), and low physical capacity (p < 0.001). The vitamin D level recommended for treating osteoporosis (i.e., vitamin D > 75 nmol/l) was observed in only 24% of patients, and 42% of patients had ionized calcium levels below the reference range. According to the level of the cross-linked carboxy-terminal telopeptide of type I collagen (ICTP), 37% of patients did not have high bone turnover. We found a positive correlation between age and ICTP (p = 0.001). The risk of death was higher after the second hip fracture (p = 0.005), but we found no difference in age between patients with first and second hip fractures (p = 0.11).
CONCLUSION: After a hip fracture, a second hip fracture is a well-known risk. Nevertheless, we found that only one-third of patients with a second hip fracture had used anti-osteoporosis medication at any time previously. These findings suggested that second hip fractures were most likely to occur in patients with osteopenic T-score values, in women more often than men, and in patients with high FRAX scores and low ambulatory capacity.
© 2022. The Author(s).

Entities:  

Keywords:  BMD; Bone turnover markers; Fragile hip fracture; High bone turn over; Osteoporosis; Screening of osteoporosis; Vitamin D

Year:  2022        PMID: 35290501     DOI: 10.1007/s00402-022-04406-4

Source DB:  PubMed          Journal:  Arch Orthop Trauma Surg        ISSN: 0936-8051            Impact factor:   3.067


  37 in total

Review 1.  Role of dual-energy X-ray absorptiometry in the diagnosis and treatment of osteoporosis.

Authors:  Glen M Blake; Ignac Fogelman
Journal:  J Clin Densitom       Date:  2006-12-27       Impact factor: 2.617

Review 2.  FRAX and its applications to clinical practice.

Authors:  John A Kanis; Anders Oden; Helena Johansson; Fredrik Borgström; Oskar Ström; Eugene McCloskey
Journal:  Bone       Date:  2009-02-03       Impact factor: 4.398

Review 3.  An overview and management of osteoporosis.

Authors:  Tümay Sözen; Lale Özışık; Nursel Çalık Başaran
Journal:  Eur J Rheumatol       Date:  2016-12-30

Review 4.  Disorders of bone remodeling.

Authors:  Xu Feng; Jay M McDonald
Journal:  Annu Rev Pathol       Date:  2011       Impact factor: 23.472

5.  Developing novel prognostic biomarkers for multivariate fracture risk prediction algorithms.

Authors:  Ernest K Poku; Mark R Towler; Niamh M Cummins; Jeff D Newman
Journal:  Calcif Tissue Int       Date:  2012-07-11       Impact factor: 4.333

6.  Treatment with alendronate prevents fractures in women at highest risk: results from the Fracture Intervention Trial.

Authors:  K E Ensrud; D M Black; L Palermo; D C Bauer; E Barrett-Connor; S A Quandt; D E Thompson; D B Karpf
Journal:  Arch Intern Med       Date:  1997 Dec 8-22

Review 7.  Epidemiology and social costs of hip fracture.

Authors:  Nicola Veronese; Stefania Maggi
Journal:  Injury       Date:  2018-04-20       Impact factor: 2.586

Review 8.  Osteoporosis in the European Union: medical management, epidemiology and economic burden. A report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA).

Authors:  E Hernlund; A Svedbom; M Ivergård; J Compston; C Cooper; J Stenmark; E V McCloskey; B Jönsson; J A Kanis
Journal:  Arch Osteoporos       Date:  2013-10-11       Impact factor: 2.617

9.  European guidance for the diagnosis and management of osteoporosis in postmenopausal women.

Authors:  J A Kanis; E V McCloskey; H Johansson; C Cooper; R Rizzoli; J-Y Reginster
Journal:  Osteoporos Int       Date:  2012-10-19       Impact factor: 4.507

Review 10.  Position Statement on the Use of Bone Turnover Markers for Osteoporosis Treatment.

Authors:  So Young Park; Seong Hee Ahn; Jun-Il Yoo; Youn-Jee Chung; Yun Kyung Jeon; Byung-Ho Yoon; Ha Young Kim; Seung Hun Lee; Jehoon Lee; Seongbin Hong
Journal:  J Bone Metab       Date:  2019-11-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.